With a QIAcuity Digital PCR System, our researchers could unlock new treatments for anyone at risk of inheriting a hereditary eye condition, like Susan, Holly, or perhaps you and your loved ones.
Many of Moorfields’ world-class eye specialists are working hard to prevent, delay and treat avoidable sight loss. Your support can help them achieve it.
Our researchers are looking into developing personalised treatments for hereditary eye conditions, such as Fuchs’ Endothelial Corneal Dystrophy (FECD). This is a condition Susan, pictured above, was diagnosed with last year.
Susan’s first thought wasn’t what this would mean for her own sight, but what it could mean for her daughter, Holly.
If we can develop new personalised treatments for FECD, Susan can be sure that Holly has the best chance of retaining her eyesight in future, so she can pursue her lifelong dream of being an artist.
“It would mean everything to know my daughter Holly won’t develop FECD like me.” - Mum, Susan
So, what is the QIAcuity Digital PCR System? How does it work?
As you may already know, mutations in specific genes can cause hereditary eye conditions like FECD.
Identifying these genetic mutations and understanding how they cause disease is crucial for accurately diagnosing these eye conditions, and developing new ways to treat them.
This is what a Digital PCR System will give us. It will enable us to accurately find this genetic information, and understand more about the biological reasons for disease.
If we can understand this about someone’s genetics, we could then create a treatment plan tailored to the individual. This could in turn help them retain the eyesight they depend on to enjoy life to its fullest.
This is the science, but at heart, it’s always about changing lives…
Lives like Susan’s, like yours, and the lives of those closest to you. It affects anyone at risk of developing an eye condition and losing the eyesight they depend on to enjoy life to the fullest.
Your donation is essential. So please donate today. You’ll help fund the equipment we need, ‘future-proof’ it for years to come and help us finally unlock the genetic secrets of eye disease.